Aliaa H Abdelhakim1, Jasmine H Francis1,2, Brian P Marr1,2, Y Pierre Gobin1,3, David H Abramson1,2, Scott E Brodie1,4. 1. Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 2. Department of Ophthalmology, Weill Cornell Medical College, New York, New York, USA. 3. Department of Interventional Neuroradiology, Weill Cornell Medical College, New York, New York, USA. 4. Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Abstract
AIM: To report retinal function outcomes after ophthalmic artery chemosurgery (OAC) for advanced retinoblastoma (RB) in eyes with minimal pretreatment retinal function. METHODS: For 72 advanced RB eyes with baseline electroretinograms (ERGs) indistinguishable from noise ('extinguished') or flicker ERG amplitudes <25 µV ('poor'), ERGs were obtained before OAC and at 3 months, 1 year and 2 years after OAC. Presence of baseline retinal detachments (RDs) and their subsequent resolution or persistence was also noted. RESULTS: At 3 months, 1 year and 2 years post-OAC, 'extinguished' eyes showed 9/15, 4/11 and 2/6 detectable ERGs, respectively, and 'poor' eyes showed 19/55, 14/30 and 8/18 ERGs exceeding 25 μV, respectively. Correlations between baseline and post-OAC ERGs were poor; however, good correlation (R2) existed between ERGs post-OAC at 3 months and 1 year (0.749), at 3 months and 2 years (0.773) and at 1 year and 2 years (0.771). Overall, 49/70 eyes presented with RD; 29 RDs resolved 3 months post-OAC, with an average ERG change of +20.6 μV. Eyes with persistent RD had an average ERG change of -2.2 μV. No eyes underwent ≥25 μV change without RD resolution. CONCLUSIONS: Minimal baseline ERGs do not preclude significant recovery of retinal function after OAC. Good correlation exists between ERG outcomes at 3 months and those at subsequent follow-ups, suggesting that ERG amplitudes at 3-month post-OAC can prognosticate longer term retinal function, and that improvement is durable. For eyes presenting with RD, RD resolution is necessary but not sufficient for significant (≥25 μV) increases in ERG amplitudes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
AIM: To report retinal function outcomes after ophthalmic artery chemosurgery (OAC) for advanced retinoblastoma (RB) in eyes with minimal pretreatment retinal function. METHODS: For 72 advanced RB eyes with baseline electroretinograms (ERGs) indistinguishable from noise ('extinguished') or flicker ERG amplitudes <25 µV ('poor'), ERGs were obtained before OAC and at 3 months, 1 year and 2 years after OAC. Presence of baseline retinal detachments (RDs) and their subsequent resolution or persistence was also noted. RESULTS: At 3 months, 1 year and 2 years post-OAC, 'extinguished' eyes showed 9/15, 4/11 and 2/6 detectable ERGs, respectively, and 'poor' eyes showed 19/55, 14/30 and 8/18 ERGs exceeding 25 μV, respectively. Correlations between baseline and post-OAC ERGs were poor; however, good correlation (R2) existed between ERGs post-OAC at 3 months and 1 year (0.749), at 3 months and 2 years (0.773) and at 1 year and 2 years (0.771). Overall, 49/70 eyes presented with RD; 29 RDs resolved 3 months post-OAC, with an average ERG change of +20.6 μV. Eyes with persistent RD had an average ERG change of -2.2 μV. No eyes underwent ≥25 μV change without RD resolution. CONCLUSIONS: Minimal baseline ERGs do not preclude significant recovery of retinal function after OAC. Good correlation exists between ERG outcomes at 3 months and those at subsequent follow-ups, suggesting that ERG amplitudes at 3-month post-OAC can prognosticate longer term retinal function, and that improvement is durable. For eyes presenting with RD, RD resolution is necessary but not sufficient for significant (≥25 μV) increases in ERG amplitudes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
Electrophysiology; Retina; Treatment Surgery
Authors: Paula Schaiquevich; Alejandro Ceciliano; Natalia Millan; Paula Taich; Francisco Villasante; Adriana C Fandino; Julieta Dominguez; Guillermo L Chantada Journal: Pediatr Blood Cancer Date: 2012-09-28 Impact factor: 3.167
Authors: Sotiria Palioura; Y Pierre Gobin; Scott E Brodie; Brian P Marr; Ira J Dunkel; David H Abramson Journal: Pediatr Blood Cancer Date: 2012-04-10 Impact factor: 3.167
Authors: Catherine Y Liu; Gowtham Jonna; Jasmine H Francis; Brian P Marr; David H Abramson; Scott E Brodie Journal: Doc Ophthalmol Date: 2013-11-09 Impact factor: 2.379
Authors: Carol L Shields; Fairooz P Manjandavida; Sara E Lally; Giulia Pieretti; Sruthi A Arepalli; Emi H Caywood; Pascal Jabbour; Jerry A Shields Journal: Ophthalmology Date: 2014-03-21 Impact factor: 12.079
Authors: Jasmine H Francis; David H Abramson; Y Pierre Gobin; Brian P Marr; Ira J Dunkel; Elyn R Riedel; Scott E Brodie Journal: PLoS One Date: 2014-01-20 Impact factor: 3.240
Authors: Lucy V Cobbs; Jasmine H Francis; Ira J Dunkel; Y Pierre Gobin; Scott E Brodie; David H Abramson Journal: Pediatr Blood Cancer Date: 2020-12-23 Impact factor: 3.838
Authors: Paula Schaiquevich; Jasmine H Francis; María Belén Cancela; Angel Montero Carcaboso; Guillermo L Chantada; David H Abramson Journal: Front Oncol Date: 2022-04-01 Impact factor: 5.738
Authors: Megan A Rowlands; Ijah Mondesire-Crump; Ariana Levin; Audrey Mauguen; Jasmine H Francis; Ira J Dunkel; Scott E Brodie; Y Pierre Gobin; David H Abramson Journal: PLoS One Date: 2018-04-26 Impact factor: 3.240